AI Engines For more Details: Perplexity Kagi Labs You
Gastric Ulcers: Irsogladine maleate is effective in treating gastric ulcers, which are open sores that develop on the lining of the stomach. It helps promote the healing of ulcers by enhancing the protective mechanisms of the stomach lining and reducing acid secretion.
Gastritis: Gastritis is inflammation of the stomach lining, which can cause symptoms such as abdominal pain, nausea, vomiting, bloating, and indigestion. Irsogladine maleate helps alleviate symptoms of gastritis by reducing inflammation and promoting the healing of the stomach mucosa.
Cytoprotective Effect: Irsogladine maleate exerts a cytoprotective effect on the stomach mucosa, meaning it helps protect the stomach lining from damage caused by various factors such as excess stomach acid, alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), and stress.
Mucus Production: Irsogladine maleate stimulates the production of mucus in the stomach, which forms a protective barrier over the stomach lining and helps prevent damage from gastric acid and other irritants.
Enhanced Blood Flow: By improving blood flow to the stomach mucosa, irsogladine maleate promotes tissue repair and regeneration, aiding in the healing of gastric ulcers and gastritis.
Symptom Relief: Patients taking irsogladine maleate typically experience relief from symptoms such as abdominal pain, discomfort, and indigestion associated with gastric ulcers and gastritis.
Mode of Action: Irsogladine maleate works by inhibiting the activity of certain enzymes involved in gastric acid secretion, such as histamine H2 receptors and proton pump ATPase. By reducing acid production, it helps create a less acidic environment in the stomach, which is conducive to ulcer healing and symptom relief.
Dosage Forms: Irsogladine maleate is available in various dosage forms, including tablets, capsules, and oral suspensions. The dosage and frequency of administration may vary depending on the severity of the condition being treated and the patient's response to treatment.
Side Effects: Common side effects of irsogladine maleate may include diarrhea, abdominal discomfort, nausea, and headache. These side effects are usually mild and transient.
Contraindications: Irsogladine maleate is contraindicated in individuals with a known hypersensitivity to the medication or any of its components. It should be used with caution in patients with severe liver or kidney impairment.
Drug Interactions: Irsogladine maleate may interact with certain medications, such as antacids, H2-receptor antagonists, and proton pump inhibitors, potentially affecting their absorption or efficacy. Patients should inform their healthcare provider about all medications they are taking before starting irsogladine maleate therapy.
Pregnancy and Lactation: The safety of irsogladine maleate during pregnancy and lactation has not been established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
| Allergies | 0.7 | 0 | 0 |
| Allergy to milk products | 0.4 | 0.2 | 1 |
| Alzheimer's disease | 0.6 | 1 | -0.67 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.4 | 0.5 |
| Ankylosing spondylitis | 0.6 | 0.4 | 0.5 |
| Anorexia Nervosa | 0.3 | -0.3 | |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.2 | -0.2 | |
| Atherosclerosis | 0 | 0 | |
| Atrial fibrillation | 0.3 | 0.3 | 0 |
| Autism | 1.4 | 1.7 | -0.21 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Bipolar Disorder | 0.3 | 0.3 | |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.3 | 0.1 | 2 |
| Celiac Disease | 1.2 | 0.1 | 11 |
| Cerebral Palsy | 0.1 | 0.1 | 0 |
| Chronic Fatigue Syndrome | 1.2 | 0.8 | 0.5 |
| Chronic Kidney Disease | 0.6 | 0.3 | 1 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.4 | |
| Chronic Urticaria (Hives) | 0.6 | 0.4 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 0.1 | 5 |
| Colorectal Cancer | 1 | 0.2 | 4 |
| Constipation | 0.9 | 0.9 | |
| Coronary artery disease | 0.4 | 0.4 | |
| COVID-19 | 1.2 | 2 | -0.67 |
| Crohn's Disease | 1.6 | 0.8 | 1 |
| cystic fibrosis | 0.5 | 0.1 | 4 |
| deep vein thrombosis | 0.5 | 0.1 | 4 |
| Depression | 2.2 | 1.3 | 0.69 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.4 | 0.5 | -0.25 |
| Endometriosis | 0.7 | 0.7 | |
| Epilepsy | 0.7 | 0.2 | 2.5 |
| Fibromyalgia | 0.5 | -0.5 | |
| Functional constipation / chronic idiopathic constipation | 1.6 | 0.6 | 1.67 |
| gallstone disease (gsd) | 0.2 | 0.2 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.1 | 9 |
| Generalized anxiety disorder | 0.8 | 0.1 | 7 |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.1 | 0.1 | |
| Halitosis | 0.1 | 0.1 | 0 |
| Hashimoto's thyroiditis | 0.2 | 0.1 | 1 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.9 | 0.2 | 3.5 |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.2 | 0.2 | 0 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 0.4 | 0.5 | -0.25 |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.7 | -0.7 | |
| Inflammatory Bowel Disease | 1.3 | 1 | 0.3 |
| Insomnia | 0.2 | 0.1 | 1 |
| Intelligence | 0.4 | 0.4 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0.9 | 1.2 | -0.33 |
| Liver Cirrhosis | 0.4 | 0.2 | 1 |
| Long COVID | 1.6 | 0.4 | 3 |
| Lung Cancer | 0.3 | 0 | 0 |
| ME/CFS with IBS | 0.1 | 0.1 | 0 |
| ME/CFS without IBS | 0.5 | 0.1 | 4 |
| Metabolic Syndrome | 1.4 | 1.6 | -0.14 |
| Mood Disorders | 2.3 | 1.3 | 0.77 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.4 | 0.9 | -1.25 |
| Multiple system atrophy (MSA) | 0.3 | 0.3 | |
| Neuropathy (all types) | 0.1 | 0.2 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | 0.5 | -1.5 |
| Obesity | 0.7 | 0.6 | 0.17 |
| obsessive-compulsive disorder | 2.1 | 0.6 | 2.5 |
| Osteoarthritis | 0.6 | 0.6 | |
| Osteoporosis | 0.3 | 0.1 | 2 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.5 | 0.8 | -0.6 |
| Polycystic ovary syndrome | 0.9 | 0 | 0 |
| primary biliary cholangitis | 0.4 | -0.4 | |
| Psoriasis | 0.8 | 0.1 | 7 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.4 | 0.5 |
| Rosacea | 0 | 0 | |
| Schizophrenia | 0.5 | 0.5 | |
| Sjögren syndrome | 0.2 | 0.7 | -2.5 |
| Sleep Apnea | 0.1 | -0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.1 | 4 |
| Systemic Lupus Erythematosus | 0.9 | 0.9 | |
| Tic Disorder | 0.7 | 0.7 | |
| Tourette syndrome | 0 | 0.1 | 0 |
| Type 1 Diabetes | 1.3 | 0.7 | 0.86 |
| Type 2 Diabetes | 2.1 | 2.1 | 0 |
| Ulcerative colitis | 0.9 | 1.2 | -0.33 |
| Unhealthy Ageing | 1.5 | 0.4 | 2.75 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.